Edwards Lifesciences Corporation (EW) Receives Price Target

Edwards Lifesciences Corporation (EW) : Average target price received by Edwards Lifesciences Corporation (EW) is $126.36 with an expected standard deviation of $10.13. The most aggressive target on the stock is $140, whereas the most downbeat target is $105. 14 financial analysts are currently covering the stock.

Edwards Lifesciences Corporation (EW) : Zacks Investment Research ranks Edwards Lifesciences Corporation (EW) as 2, which is a Buy recommendation. 11 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 16 research analysts is 1.53, which indicates as a Buy.


Also, JMP Securities maintains their rating on the shares of Edwards Lifesciences Corporation (NYSE:EW). The current rating of the shares is Market Outperform. Equity Analysts at the Firm raises the price target to $130 per share from $125 per share. The rating by the firm was issued on July 28, 2016.

Edwards Lifesciences Corporation (NYSE:EW): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $115.50 and $114.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $115.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $115.87, notching a gain of 0.62% for the day. The total traded volume was 1,097,907 . The stock had closed at $115.16 on the previous day.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *